On January 29, 2026, Moderna announced a strategic collaboration agreement with Recordati to advance Moderna’s mRNA-3927, an investigational product for treating propionic acidemia (PA), through the final stages of clinical development as well as global commercialization upon approval. This partnership arrives at a historic moment for the Italian pharma company, which celebrates its centennial anniversary … Moderna and Recordati Form Strategic Alliance to Commercialize mRNA Therapy for Propionic Acidemia Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.